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One of the key issues affecting the health of European citizens today is a shortage of medicines. This is an EU-wide problem and there are many complex issues involved \[[@B1].\]

In the case of drugs for rare cancer patients, it can be as "simple" as high prices due to a, by definition, smaller market, so return on investment for pharmaceutical companies is difficult, if not impossible.

Even low profit margins can result in non-viable production lines, while so-called industry consolidation can lead to fewer older medicines which are often less profitable nowadays \[[@B2]\].

And, obviously, sudden health emergencies, for example large outbreaks of a certain disease or virus, can lead to shortages, often at a critical level.

But there are other factors, and the EU must face them as part of its moral duty and stated aim of giving the best healthcare possible, including more access and better diagnoses, for all 500 million citizens across the current 28 Member States \[[@B3]\].

One of the main pillars of the EU is equality for all, and surely there is no more important arena than that of healthcare.

The European Medicines Agency\'s (EMA) final common position on shortages, published several years ago and written in tandem with groups such as the European Organisation of Rare Diseases, the Pharmaceutical Group of the European Union, the European Public Health Alliance and others, defined supply shortage of medicine "as a situation in which the total supply of an authorised medicine or of a medicine used on a compassionate basis is inadequate to meet the current or projected demand at the patient level" \[[@B4]\].

"The shortage may be local, national, European or international," the document added.

The document also pointed out that Article 81 of the EU Directive on Medicines for Human Use was "intended to ensure adequate supply of any given product to the market. However, there is extensive evidence of situations where pharmacies can\'t obtain the medicines that they need for their patients".

In 2013, the EMA chose to establish a "public catalogue" of potential, ongoing and resolved shortages of medicines that are authorised at EU level, or that are being evaluated as part of a EU procedure.

Unfortunately, the catalogue does not give a complete overview of all medicine shortages occurring across the Union, because most shortages are dealt with at national level or exceed the EMA\'s mandate.

In the EU\'s favour is the fact that its Medicines Agencies Network Strategy up to 2020 has placed the availability of authorised medicinal products as a key public health priority.
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One major issue with shortages is that, while different EU countries have different levels of resources which can be a factor, medicine shortages happen in the richer as well as the poorer Member States. These can result from reasons as diverse as a lack of raw materials, manufacturing issues, high demand, basic economics and more besides \[[@B5]\].

Not only that, but the bench-to-bedside time scales (and costs) plus a lack of efficiency in the supply chain can lead to shortages. Then we have approval times and potential quality risks when there are attempts to speed these up \[[@B6]\].

Whatever the reason(s), shortages of medicines eventually lead to higher costs for the 28 healthcare systems operating individually under their own competence across the EU \[[@B7]\].

Shortages of vaccines, essentially to immunise children, are even occurring due to high demand and quality problems.

When it comes to patients, which is what it is all about, shortages can often mean lower quality and safety of care, with the added distress that these cause.

The shortages also mean that healthcare professionals are able to spend less time with their patients as they struggle to manage the shortage. Add to this the reality that unavailable medicines are often substituted with less effective and/or more expensive alternatives.

The latter incidence can lead to more medication errors due to a lack of familiarity with the replacement product, with the knock-on effect of more adverse reactions, worse patient outcomes and, in the worst case, even death.

It is clear that the potential negative consequences of a shortage can be huge \[[@B8]\].

"Not an Ordinary Commodity" {#sec1_3}
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Unfortunately, reports of medicine shortages in the EU are on the rise, with all classes of medicines being affected. In a number of Member States, national authorities are now monitoring the situation, for example by setting up websites in order to inform the general public.

Also "advance notice systems" are often in place in a bid to mitigate the effects of shortages, and rely on data from medicine supply chains, but there is only so much that national medicines regulatory authorities can do as they cannot force a manufacturer to produce a certain medicine.

Monitoring the supply chain can help, as it allows for redistribution to areas of need. But this is usually at a national level only, as the EU does not have overall competency in this area \[[@B9]\].

Meanwhile, there have been calls for legislation that requires "early warning" to the EMA from companies about even a potential shortage, rather than the companies waiting for it to actually occur.

More recently, at an Informal Meeting of Health Ministers held in October of last year, under the Slovak Presidency of the EU, the background paper stated that: "Short and long-term shortages of medicinal products have been a global problem for the past decade and over the last few years it has also increasingly affected the EU."

It went on to state that shortages "have affected all classes of medicines including injectable chemotherapy agents, anaesthetic agents, intravenous nutrition, vaccines, electrolyte products, enzyme replacement products, radio-pharmaceuticals and more."

"Medicinal products are not an ordinary commodity and their unavailability is a serious problem as it may compromise patient care and can have a significant impact on the health systems of Member States," it added.

One of the conclusions cited regional cross-border cooperation, and the common purchasing of medicines, as part of any possible solutions. A similar plan is currently being tried by Belgium, Luxembourg and the Netherlands in the area of orphan drugs prices, so far with limited success \[[@B10]\].

However, it is clear that further cooperation is necessary between all stakeholders, including Member States, to make the problem of drug shortages a thing of the past.
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